Market Cap 4.19B
Revenue (ttm) 47.07M
Net Income (ttm) -223.86M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -475.59%
Debt to Equity Ratio 0.00
Volume 532,186
Avg Vol 756,528
Day's Range N/A - N/A
Shares Out 71.50M
Stochastic %K 38%
Beta 2.26
Analysts Strong Sell
Price Target $67.09

Company Profile

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis. The company also develops STAT6, a type 2 inflammation in a...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 285 5300
Address:
500 North Beacon Street, 4th Floor, Watertown, United States
outlawinvestor1
outlawinvestor1 Oct. 26 at 11:57 AM
$CCCC nice updated overview of the tpd landscape. $ARVN $NRIX $GLUE $KYMR
1 · Reply
IN0V8
IN0V8 Oct. 24 at 7:37 PM
$KYMR Buy B. Riley raises target price to $80 from $60
0 · Reply
notreload_ai
notreload_ai Oct. 24 at 1:20 PM
Citi maintained a "Buy" rating on $KYMR , setting an $80 price target. They also added an "upside 90-day catalyst watch," anticipating positive Phase 1b study data for KT-621 in atopic dermatitis by mid-to-late November.
0 · Reply
oaksapollo
oaksapollo Oct. 22 at 1:25 PM
$NRIX only one thing surprised me in the deck and it’s how bad KT-474 data looks. It’s almost as if they’re intentionally not fully degrading the target. Any $KYMR investors understand this? It appears that the DMSO control for KT-474 had less IRAK4 expression to start with, but you can still see a band at every concentration of KT-474.
1 · Reply
JarvisFlow
JarvisFlow Oct. 22 at 11:33 AM
BTIG updates rating for Kymera Therapeutics ( $KYMR ) to Buy, target set at 59 → 75.
0 · Reply
JarvisFlow
JarvisFlow Oct. 21 at 12:38 PM
Mizuho updates rating for Kymera Therapeutics ( $KYMR ) to Outperform, target set at 81.
0 · Reply
JarvisFlow
JarvisFlow Oct. 17 at 3:25 PM
Citigroup has adjusted their stance on Kymera Therapeutics ( $KYMR ), setting the rating to Buy with a target price of 60 → 80.
0 · Reply
MikeyNJ
MikeyNJ Oct. 16 at 1:50 AM
$KYMR One of my top picks in biotech. I have thought for a while now that this would eventually get bought for approx. $85/share most likely by Sanofi. It's amazing that few know about this one as reflected in the low board activity.
0 · Reply
justiceforb_85
justiceforb_85 Oct. 14 at 2:02 AM
$KYMR really looking forward to KT-621 data later this year in atopic dermatitis.
0 · Reply
georgenobest
georgenobest Oct. 12 at 2:31 PM
$KYMR CATX more than 300% upside. Catalyst coming next week. The move just started https://in.investing.com/news/analyst-ratings/btig-initiates-coverage-on-perspective-therapeutics-stock-with-buy-rating-93CH-5038968
0 · Reply
Latest News on KYMR
The Best Small-Cap Stocks to Buy Now

Aug 12, 2025, 9:47 AM EDT - 2 months ago

The Best Small-Cap Stocks to Buy Now

DNLI WAY


Kymera Therapeutics Announces Proposed Public Offering

Jun 25, 2025, 4:05 PM EDT - 4 months ago

Kymera Therapeutics Announces Proposed Public Offering


Kymera Therapeutics Announces Sanofi IRAK4 Collaboration Update

Jun 25, 2025, 7:05 AM EDT - 4 months ago

Kymera Therapeutics Announces Sanofi IRAK4 Collaboration Update


Kymera: Protein Degradation Could Drive Dupixent-Like Value

Dec 7, 2024, 1:07 AM EST - 11 months ago

Kymera: Protein Degradation Could Drive Dupixent-Like Value


outlawinvestor1
outlawinvestor1 Oct. 26 at 11:57 AM
$CCCC nice updated overview of the tpd landscape. $ARVN $NRIX $GLUE $KYMR
1 · Reply
IN0V8
IN0V8 Oct. 24 at 7:37 PM
$KYMR Buy B. Riley raises target price to $80 from $60
0 · Reply
notreload_ai
notreload_ai Oct. 24 at 1:20 PM
Citi maintained a "Buy" rating on $KYMR , setting an $80 price target. They also added an "upside 90-day catalyst watch," anticipating positive Phase 1b study data for KT-621 in atopic dermatitis by mid-to-late November.
0 · Reply
oaksapollo
oaksapollo Oct. 22 at 1:25 PM
$NRIX only one thing surprised me in the deck and it’s how bad KT-474 data looks. It’s almost as if they’re intentionally not fully degrading the target. Any $KYMR investors understand this? It appears that the DMSO control for KT-474 had less IRAK4 expression to start with, but you can still see a band at every concentration of KT-474.
1 · Reply
JarvisFlow
JarvisFlow Oct. 22 at 11:33 AM
BTIG updates rating for Kymera Therapeutics ( $KYMR ) to Buy, target set at 59 → 75.
0 · Reply
JarvisFlow
JarvisFlow Oct. 21 at 12:38 PM
Mizuho updates rating for Kymera Therapeutics ( $KYMR ) to Outperform, target set at 81.
0 · Reply
JarvisFlow
JarvisFlow Oct. 17 at 3:25 PM
Citigroup has adjusted their stance on Kymera Therapeutics ( $KYMR ), setting the rating to Buy with a target price of 60 → 80.
0 · Reply
MikeyNJ
MikeyNJ Oct. 16 at 1:50 AM
$KYMR One of my top picks in biotech. I have thought for a while now that this would eventually get bought for approx. $85/share most likely by Sanofi. It's amazing that few know about this one as reflected in the low board activity.
0 · Reply
justiceforb_85
justiceforb_85 Oct. 14 at 2:02 AM
$KYMR really looking forward to KT-621 data later this year in atopic dermatitis.
0 · Reply
georgenobest
georgenobest Oct. 12 at 2:31 PM
$KYMR CATX more than 300% upside. Catalyst coming next week. The move just started https://in.investing.com/news/analyst-ratings/btig-initiates-coverage-on-perspective-therapeutics-stock-with-buy-rating-93CH-5038968
0 · Reply
georgenobest
georgenobest Oct. 11 at 6:41 PM
$KYMR CATX more than 300% upside. Catalyst coming next week. The move just started https://in.investing.com/news/analyst-ratings/btig-initiates-coverage-on-perspective-therapeutics-stock-with-buy-rating-93CH-5038968
0 · Reply
JarvisFlow
JarvisFlow Oct. 8 at 6:53 PM
B of A Securities has adjusted their stance on Kymera Therapeutics ( $KYMR ), setting the rating to Neutral with a target price of 45 → 43.
0 · Reply
FadeScout
FadeScout Oct. 5 at 9:38 AM
$KYMR Biotech with novel approach. High short interest. Potential squeeze setup if data positive. High risk/reward.
0 · Reply
MaverikIT
MaverikIT Oct. 3 at 7:32 PM
0 · Reply
JarvisFlow
JarvisFlow Oct. 1 at 1:38 PM
Oppenheimer updates rating for Kymera Therapeutics ( $KYMR ) to Outperform, target set at 53 → 63.
0 · Reply
JarvisFlow
JarvisFlow Sep. 30 at 2:32 PM
Truist Securities has adjusted their stance on Kymera Therapeutics ( $KYMR ), setting the rating to Buy with a target price of 53 → 68.
0 · Reply
SannieVerraderlijk
SannieVerraderlijk Sep. 29 at 11:02 AM
0 · Reply
MaverikIT
MaverikIT Sep. 26 at 5:17 PM
$KYMR - not bad da month
0 · Reply
MaxDanger
MaxDanger Sep. 21 at 1:10 AM
$NRIX This degrader sector has valuations all over the place. $KYMR has a $3.5 billion market cap and remains farther from commercialization than $NRIX, which has a $650 million market cap. To me the $NRIX sell-off appears overly tethered to $ARVN’s Phase 3 VERITAC-2 trial disappointment. It caused a 40% drop in ARVN’s stock in March and $NRIX has followed. That failure overshadows NRIX’s own progress, including FDA-cleared INDs for its IRAK4 degrader in inflammatory diseases and brain-penetrant degraders showcased at AACR 2025, showing that NRIX closer to clinical milestones. $NRIX should be most compared to $ONC. $ONC’s lead degrader is slightly ahead in development, but NRIX’s platform offers superior breadth, validated partnerships, and innovative features like CNS penetration and dual-targeting. These advantages position $NRIX for outsized value creation. NRIX trades at a fraction of the implied worth of Onc degrader franchise, suggests an NRIX cap of at least $2 bln.
1 · Reply
JarvisFlow
JarvisFlow Sep. 18 at 1:53 PM
HC Wainwright & Co. updates rating for Kymera Therapeutics ( $KYMR ) to Buy, target set at 60 → 70.
0 · Reply
notreload_ai
notreload_ai Sep. 18 at 12:32 PM
H.C. Wainwright increased the price target for $KYMR to $70 from $60, maintaining a Buy rating. The company shared positive data on KT-621, its oral STAT6 degrader.
0 · Reply
JarvisFlow
JarvisFlow Sep. 17 at 11:00 AM
Barclays updates rating for Kymera Therapeutics ( $KYMR ) to Overweight, target set at 60.
0 · Reply